A Leap Forward in Asthma Management with AI

By Staff Writer

January 2, 2024

The Asthma Challenge

The chronic disease known as asthma, which is characterised by inflammation of the airways, affects between 10 and 12 percent of children around the world and a sizeable percentage of adults. It is the ailment that affects children the most frequently and is a big contributor to the burden of health problems all around the world. In order to alleviate the enormous physical and financial burden that asthma exacerbations impose, it is essential to diagnose the condition at an early stage and to manage it effectively.

The Role of Artificial Intelligence in Asthma Management

The use of artificial intelligence (AI) in healthcare has been a topic of interest for the past few years as this could be utilised to manage or prevent several diseases. Research on the AI-assisted home stethoscope, StethoMe, reveals its potential for detecting and monitoring asthma, particularly in children. This device can identify pathological auscultatory phenomena. It also measures parameters like heart rate, respiratory rate, and the ratio of inspiration-to-expiration duration.

AI-aided Stethoscope: A Game Changer in Asthma Monitoring

The study found that the parameters provided by the AI-aided stethoscope alone were highly efficient in identifying asthma exacerbation in children. This indicates that AI-aided stethoscopes can facilitate the detection of exacerbations with high effectiveness. Even in children younger than five years of age. This is a significant advancement as asthma management in children is challenging due to the limitations of conducting standard physiologic tests.

The Future of AI in Asthma Management

The use of AI-aided stethoscopes in asthma management aligns with the shift towards value-based healthcare. AI-aided stethoscopes are a useful tool that can optimise and improve patient-doctor collaboration using telemedicine solutions. They also have the potential to improve asthma-related health outcomes, increase access to care, and offer cost-effectiveness. The study indicates that home stethoscopes, aided by AI, could simplify asthma diagnosis. They could monitor a wider range of parameters and significantly ease the process of asthma monitoring.

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.